Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: Serum IL-7 as a prognostic marker

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 28, Issue 2, 2011, Pages 113-122

  Tachibana, K ^a   Inoue, Y ^a   Nishiyama, A ^a   Sugimoto, C ^a   Matsumuro, A ^a   Hirose, M ^a   Kitaichi, M ^a   Akira, M ^a   Arai, T ^a   Hayashi, S ^a   Inoue, Yoshikazu ^a  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

Acute exacerbation; Cytokine; Hemoperfusion; Idiopathic pulmonary fibrosis; Polymyxin

Indexed keywords

CHEMOKINE; CORTICOSTEROID; GAMMA INTERFERON; INTERLEUKIN 1BETA; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYMYXIN B;

AIR CONDITIONING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; FEMALE; HEMOPERFUSION; HUMAN; IDIOPATHIC DISEASE; LUNG FIBROSIS; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADRENAL CORTEX HORMONES; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; HEMOPERFUSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERLEUKIN-17; JAPAN; KAPLAN-MEIER ESTIMATE; POLYMYXIN B; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 81455131952     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646-64.
2. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-7.
3. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006; 27: 143-50. (Pubitemid 43092678)
4. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005; 128: 3310-5. (Pubitemid 41698656)
5. Kondoh Y, Taniguchi H, Katsuta T, et al. Risk Factors of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27: 103-10.
6. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993; 103: 1808-12. (Pubitemid 23174318)
7. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-43. (Pubitemid 47503070)
8. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol 1997; 168: 79-83. (Pubitemid 27014751)
9. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003; 22: 821-6. (Pubitemid 37369573)
10. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE, Jr. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133: 226-32.
11. Tomioka H, Kuwata Y, Imanaka K, et al. A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. Respirology 2005; 10: 449-55. (Pubitemid 43942613)
12. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37: 356-63.
13. Kase Y, Obata T, Okamoto Y, et al. Removal of 2-arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock. Ther Apher Dial 2008; 12: 374-80.
14. Kohro S, Imaizumi H, Yamakage M, et al. Anandamide absorption by direct hemoperfusion with polymixin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J Anesth 2006; 20: 11-6. (Pubitemid 43125774)
15. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445-52.
16. Tsushima K, Kubo K, Koizumi T, et al. Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome. J Clin Apher 2002; 17: 97-102. (Pubitemid 34809559)
17. Nakamura T, Kawagoe Y, Matsuda T, et al. Effect of polymyxin B-immobilized fiber on blood metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in acute respiratory distress syndrome patients. Blood Purif 2004; 22: 256-60. (Pubitemid 39177729)
18. Seo Y, Abe S, Kurahara M, et al. Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2006; 45: 1033-8. (Pubitemid 44613581)
19. Enomoto N, Suda T, Uto T, et al. Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. Respirology 2008; 13: 452-60. (Pubitemid 351503154)
20. Noma S, Matsuyama W, Mitsuyama H, et al. Two cases of acute exacerbation of interstitial pneumonia treated with polymyxin B-immobilized fiber column hemoperfusion treatment. Intern Med 2007; 46: 1447-54. (Pubitemid 47455772)
21. Hara S, Ishimoto H, Sakamoto N, et al. Direct Hemoperfusion Using Immobilized Polymyxin B in Patients with Rapidly Progressive Interstitial Pneumonias: A Retrospective Study. Respiration 2010; Dec 1.: [Epub ahead of print].
22. Schmidt K, Martinez-Gamboa L, Meier S, et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009; 11: R111.
23. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-9.
24. Lynch DA, David Godwin J, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172: 488-93. (Pubitemid 41117395)
25. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-lb in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-33. (Pubitemid 38056223)
26. Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman JR, Jr. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 1997; 43: 1749-56.
27. Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008; 177: 752-62. (Pubitemid 351490562)
28. Al-Hameed FM, Sharma S. Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis. Can Respir J 2004; 11: 117-22. (Pubitemid 38519170)
29. Huang M, Sharma S, Zhu LX, et al. IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J Clin Invest 2002; 109: 931-7.
30. Zhang L, Keane MP, Zhu LX, et al. Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosis. J Biol Chem 2004; 279: 28315-9. (Pubitemid 38900110)
31. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21: 791-808.
32. Prior C, Haslam PL. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases. Clin Exp Immunol 1992; 88: 280-7.
33. King TE, Jr., Albera C, Bradford WZ, et al. Effect of interferon gamma-lb on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-8.
34. Abe S, Seo Y, Hayashi H, et al. Neutrophil Adsorption by Polymyxin B-Immobilized Fiber Column for Acute Exacerbation in Patients with Interstitial Pneumonia: A Pilot Study. Blood Purif 2010; 29: 1-6.
35. Nishibori M, Takahashi HK, Katayama H, et al. Specific Removal of Monocytes from Peripheral Blood of Septic Patients by Polymyxin B-immobilized Filter Column. Acta Med Okayama 2009; 63: 65-9.
36. Graves DT, Nooh N, Gillen T, et al. IL-1 plays a critical role in oral, but not dermal, wound healing. J Immunol 2001; 167: 5316-20. (Pubitemid 33009770)
37. Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage-the role of oxygen, shock, and related factors. A review. Am J Pathol 1976; 85: 209-28.
38. Sugiura T, Goto K, Ninchoji T, et al. Cytokine profiles before and after exchange transfusion in a neonate with transient myeloproliferative disorder and hepatic fibrosis. J Pediatr Hematol Oncol 2010; 32: e164-6.
39. Tiitto L, Bloigu R, Heiskanen U, Paakko P, Kinnula VL, KaarteenahoWiik R. Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia. Thorax 2006; 61: 1091-5. (Pubitemid 44852029)